NorthWest Biotherapeutics Inc (NWBO)

[notbrad]

Excellent, and thank you for this. This puts to rest, at least for me, the debate about pseudo versus rapid progressors.

In the 55 information arm slide, the left column has the description "rapid progressors, pseudo progressors & insufficient doses". I presume this applies to the SOC column too; not just for the DCVax-L column. So I take it that the 8 - 11 months improvement over SOC still stands valid. The references you included seem to indicate that roughly 20% of the rapid progressor population "could" be pseudos but very difficult to determine precisely. The new information in the slide seem to suggest that the median could be around 20 months and comparable to the 18 months suggested in the slide. This is comforting while we await more details.